Table 4 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Authors

Publication Details

Published
2025-10-13
DOI
https://doi.org/10.1158/2767-9764.30344799
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Table 4 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kyoichi Okishio, Hiroki Izumi, Kohei Shitara, Hisashi Hosaka et al.
Cancer Immunotherapy and Biomarkers
article

Table 4 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kyoichi Okishio, Hiroki Izumi, Kohei Shitara, Hisashi Hosaka, Kunihiro Tsuji, Yukiya Narita, Motohiro Tamiya, Hiroki Hara, Nobuhiko Seki, Akihito Tsuji, Yasunori Ushida, Toshifumi Yamaguchi, Hideaki Suna, Kensei Yamaguchi, Katsunori Shinozaki, Hiroshi Tanaka, Yosuke Tamura, Naohiro Watanabe, Takeshi Shiraishi
article en

Abstract

No abstract available for this paper.
Openalex Percentile: Top 61%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.